Edwards Lifesciences (EW) Expected to Announce Earnings on Tuesday

Edwards Lifesciences (NYSE:EW) is projected to post its Q4 2025 results before the market opens on Tuesday, February 10th. Analysts expect Edwards Lifesciences to post earnings of $0.61 per share and revenue of $1.5425 billion for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, February 13, 2026 at 12:00 AM ET.

Edwards Lifesciences Trading Up 1.5%

Shares of EW opened at $82.58 on Tuesday. The stock has a market capitalization of $47.92 billion, a PE ratio of 35.59, a P/E/G ratio of 3.13 and a beta of 0.94. The company’s fifty day moving average is $84.72 and its 200 day moving average is $81.07. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. Edwards Lifesciences has a fifty-two week low of $65.94 and a fifty-two week high of $87.89.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,700 shares of the business’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total value of $650,419.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at $3,370,184.06. The trade was a 16.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $85.70, for a total transaction of $87,328.30. Following the completion of the transaction, the vice president owned 22,002 shares in the company, valued at $1,885,571.40. This represents a 4.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 57,824 shares of company stock worth $4,863,323. 0.34% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. JPL Wealth Management LLC bought a new stake in Edwards Lifesciences during the 3rd quarter valued at $25,000. Rakuten Securities Inc. increased its stake in shares of Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after buying an additional 302 shares during the period. Kelleher Financial Advisors purchased a new position in shares of Edwards Lifesciences during the third quarter valued at $50,000. Chapman Financial Group LLC bought a new stake in shares of Edwards Lifesciences in the second quarter valued at about $63,000. Finally, Financial Life Planners purchased a new stake in Edwards Lifesciences in the third quarter worth about $93,000. Institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on EW shares. Wells Fargo & Company set a $100.00 price target on shares of Edwards Lifesciences in a report on Thursday, December 18th. Citigroup reaffirmed a “buy” rating and issued a $101.00 price objective (up from $96.00) on shares of Edwards Lifesciences in a research note on Thursday, December 11th. Truist Financial set a $92.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, December 5th. Evercore ISI restated an “outperform” rating and set a $94.00 price target on shares of Edwards Lifesciences in a report on Monday, January 5th. Finally, Sanford C. Bernstein restated a “market perform” rating and issued a $90.00 price target on shares of Edwards Lifesciences in a research report on Monday, November 3rd. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.82.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.